| Symbol | CBIO |
|---|---|
| Name | CRESCENT BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9708 MEDICAL CENTER DRIVE, ROCKVILLE, Maryland, 20850, United States |
| Telephone | +1 240 243-1201 |
| Fax | — |
| — | |
| Website | https://www.glycomimetics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. Additional info from NASDAQ: |
(30% Negative) CRESCENT BIOPHARMA, INC. (CBIO) Reports Q2 2026 Financial Results
Read moreCrescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Read moreNew Form 424B3 - CRESCENT BIOPHARMA, INC. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001628280-26-028415 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - CRESCENT BIOPHARMA, INC. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001628280-26-026291 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - CRESCENT BIOPHARMA, INC. <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001628280-26-026285 <b>Size:</b> 1 MB
Read more(99% Neutral) CRESCENT BIOPHARMA, INC. (CBIO) Announces Clinical Development Update
Read moreCrescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07335497 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Phase1 | Locally Advanced / Metastatic Solid Tumors | Recruiting | 2026-02-17 | 2029-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | Other | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |
| CR-001 | DRUG | Phase PHASE1 | Locally Advanced / Metastatic Solid Tumors | RECRUITING | NCT07335497 |